TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14582814

Group type: EXPERIMENTAL
Intervention: Fexofenadine hydrochloride, 180 mg
Number of subjects: 495

Group type: COMPARATOR
Intervention: Cetirizine, 10 mg
Number of subjects: 495
Study: 10999556

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valproate (VPA)
Number of subjects: 0
Study: 8997048

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg.kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thiopental 5 mg.kg‐1
Number of subjects: 60
Study: 1336008

Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) administration as monochemiotherapy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) administration in combination with glutathione
Number of subjects: 33
Study: 4050769

Group type: EXPERIMENTAL
Intervention: Intervention program focusing on nutrition, physical fitness, and cigarette smoking prevention
Number of subjects: 2283
Study: 30981604

Group type: EXPERIMENTAL
Intervention: IDEA workflow for genomic analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IDEA workflow optimized for circulating tumor DNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IDEA workflow
Number of subjects: 0
Study: 29369914

Group type: EXPERIMENTAL
Intervention: ANT1 soybean extract cream
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 27374944

Group type: EXPERIMENTAL
Intervention: Annual mammography and physical examination (MA + PX) for women aged 40-49
Number of subjects: 89835

Group type: EXPERIMENTAL
Intervention: Annual mammography and physical examination (MA + PX) for women aged 50-59
Number of subjects: 89835

Group type: EXPERIMENTAL
Intervention: Including ductal carcinoma in situ with invasive cancer for women aged 40-49
Number of subjects: 89835

Group type: EXPERIMENTAL
Intervention: Including ductal carcinoma in situ with invasive cancer for women aged 50-59
Number of subjects: 89835
Study: 24942055

Group type: EXPERIMENTAL
Intervention: Morphine (0.25, 0.75 or 1.25 mg/100 cm² wound size) in hydroxyethylcellulose gel
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo applied onto the excised split-thickness donor wound
Number of subjects: 44
Study: 22275444

Group type: COMPARATOR
Intervention: Metformin monotherapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Metformin added to oral therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Metformin added to insulin therapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Higher doses of metformin
Number of subjects: 35
Study: 21242609

Group type: EXPERIMENTAL
Intervention: 08:00 hr
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 14:00 hr
Number of subjects: 20
Study: 17652651

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg daily
Number of subjects: 2434

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2434
Study: 16620045

Group type: EXPERIMENTAL
Intervention: Horsechestnut seed extract
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 12873288

Group type: EXPERIMENTAL
Intervention: Felted foam therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 54
Study: 10978026

Group type: EXPERIMENTAL
Intervention: Surgical intervention (carotid endarterectomy)
Number of subjects: 659

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Delayed endarterectomy
Number of subjects: 659

Group type: COMPARATOR
Intervention: Continued medical therapy
Number of subjects: 659
Study: 8791952

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.m. plus clarithromycin 250 mg b.d. and tinidazole 500 mg b.d. (group A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.m. plus clarithromycin 250 mg b.d. and amoxycillin 1000 mg b.d. (group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group B
Number of subjects: 100
Study: 1298088

Group type: EXPERIMENTAL
Intervention: Quinine, quinidine, and cinchonine combination (600 mg regimen)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Quinine, quinidine, and cinchonine combination (400 mg regimen)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Quinine, quinidine, and cinchonine combination
Number of subjects: 13
Study: 6098221

Group type: EXPERIMENTAL
Intervention: Systemic acyclovir (ACV) therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: COMPARATOR
Intervention: Systemic placebo
Number of subjects: 43
Study: 31408480

Group type: EXPERIMENTAL
Intervention: Algorithm based on clinical course for SJS/TEN, medical encounters for mucocutaneous lesions from SJS/TEN, and items to exclude paraneoplastic pemphigus (not using ICD-10 codes)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (randomly sampled patients)
Number of subjects: 113
Study: 28947725

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy accompanied by oral anticoagulation (OAC) - triple therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 26398126

Group type: EXPERIMENTAL
Intervention: Low injection speed (60 seconds)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Slow injection speed (100 seconds)
Number of subjects: 32
Study: 23660098

Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTI) 30 kU three times per day for 5 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 60
Study: 20872022

Group type: EXPERIMENTAL
Intervention: Laparoscopic sigmoid resection (LSR)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Open sigmoid resection (OSR)
Number of subjects: 104
Study: 19478249

Group type: EXPERIMENTAL
Intervention: RDTs plus training, guidelines, and supervision (TGS)
Number of subjects: 1540

Group type: COMPARATOR
Intervention: TGS alone
Number of subjects: 1540
Study: 18040832

Group type: EXPERIMENTAL
Intervention: Antiretroviral drugs that penetrate the blood-brain barrier (CNS penetration drugs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-penetrating antiretrovirals
Number of subjects: 0
Study: 14711748

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 1346

Group type: COMPARATOR
Intervention: Vaginal hysterectomy
Number of subjects: 1346

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 1346
Study: 11700909

Group type: EXPERIMENTAL
Intervention: Immediate free recall under articulatory suppression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate free recall after an intervening distractor task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serial position functions in semantically cued recall
Number of subjects: 0
Study: 9154765

Group type: EXPERIMENTAL
Intervention: Cellular telephones (one analogue and four digital) tested in maximal power mode
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Cellular telephones (one analogue and four digital) held over the pacemaker
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Dual-chamber pacemakers
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Single-chamber pacemakers
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Pacemakers without feed-through filters
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Pacemakers with feed-through filters
Number of subjects: 980
Study: 7899001

Group type: EXPERIMENTAL
Intervention: Low dose of Tiapride
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High dose of Tiapride
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Follow-up observation without medication
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tiapride (general)
Number of subjects: 10
Study: 3674234

Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saccharin
Number of subjects: 30
Study: 31934811

Group type: EXPERIMENTAL
Intervention: Acidic 30% hydrogen peroxide (HP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neutral 30% hydrogen peroxide (HP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alkaline 30% hydrogen peroxide (HP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Distilled water (Control)
Number of subjects: 20
Study: 30173161

Group type: EXPERIMENTAL
Intervention: Cloxacillin
Number of subjects: 300

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 300
Study: 27411482

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) + naproxen (NPX)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (PBO) + naproxen (NPX)
Number of subjects: 150
Study: 25393414

Group type: EXPERIMENTAL
Intervention: Psychodynamic group art therapy plus treatment as usual
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 58
Study: 24330706

Group type: EXPERIMENTAL
Intervention: Physical training (aerobic training, 5 times a week, for 50 minutes)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Relaxation sessions (5 times a week, for 50 minutes)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 100

Group type: COMPARATOR
Intervention: Relaxation sessions
Number of subjects: 100
Study: 20429738

Group type: EXPERIMENTAL
Intervention: Structured home visit by GP and district nurse one week after discharge followed by two contacts after three and eight weeks
Number of subjects: 331

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Structured home visit by GP and district nurse
Number of subjects: 331
Study: 18831691

Group type: EXPERIMENTAL
Intervention: High-dose folate supplementation (5 mg daily)
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: High baseline folate levels
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: High parasite densities
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Age <20 years
Number of subjects: 467

Group type: COMPARATOR
Intervention: Low-/moderate-dose folate supplementation
Number of subjects: 467
Study: 16939028

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser irradiation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control for Er,Cr:YSGG
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control for CO2
Number of subjects: 32
Study: 12923794

Group type: EXPERIMENTAL
Intervention: Cognitive-existential group therapy (CEGT)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control (3 relaxation classes)
Number of subjects: 303
Study: 11153576

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) dry powder inhaler (DPI) 200 microg b.i.d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) dry powder inhaler (DPI) 400 microg b.i.d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Budesonide (BUD) Turbuhaler 400 microg b.i.d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 0
Study: 9298773

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ballistic stretching
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Stationary cycling
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (resting)
Number of subjects: 59
Study: 8262577

Group type: EXPERIMENTAL
Intervention: Loading dose diazepam (67 +/- 9.3 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional dose diazepam (200 mg)
Number of subjects: 41
Study: 3516189

Group type: EXPERIMENTAL
Intervention: promethazine 0.5 mg kg‐1 i.m. 45 min before induction of anaesthesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: cimetidine 400 mg i.m. 120 min before induction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no premedication)
Number of subjects: 60
Study: 29445881

Group type: EXPERIMENTAL
Intervention: Salivary and serum vaspin (VASP) concentrations
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Total antioxidant status (TAS)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Salivary flow
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Correlations between TAS, VASP, salivary flow, and nutritional status
Number of subjects: 90

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 90
Study: 28281845

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 20 min over left prefrontal cortex)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 16
Study: 26181573

Group type: EXPERIMENTAL
Intervention: Yoga practice (90 minutes once a week for 12 weeks, plus daily home practice for 40 minutes)
Number of subjects: 25
Study: 22887494

Group type: EXPERIMENTAL
Intervention: Heparin plus glycoprotein platelet inhibitors (GPI)
Number of subjects: 13819

Group type: EXPERIMENTAL
Intervention: Bivalirudin plus GPI
Number of subjects: 13819

Group type: EXPERIMENTAL
Intervention: Bivalirudin alone
Number of subjects: 13819

Group type: COMPARATOR
Intervention: Control group (non-US sites)
Number of subjects: 13819
Study: 22322057

Group type: EXPERIMENTAL
Intervention: Direct dissection of urogenital diaphragm
Number of subjects: 126

Group type: COMPARATOR
Intervention: Traditional operative method
Number of subjects: 126
Study: 17939042

Group type: EXPERIMENTAL
Intervention: IFN alpha + Ribavirin + 2 g Carnitine per day (group B)
Number of subjects: 70

Group type: COMPARATOR
Intervention: IFN alpha + Ribavirin (group A)
Number of subjects: 70
Study: 16783280

Group type: EXPERIMENTAL
Intervention: Genuine acupuncture to LI4 (Hegu) and LI10 (Shousanli) for 20 minutes
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Inappropriate acupuncture to PC3 (Quze) and PC6 (Neiguan) for 20 minutes
Number of subjects: 35

Group type: COMPARATOR
Intervention: No intervention control for 20 minutes
Number of subjects: 35
Study: 12837144

Group type: EXPERIMENTAL
Intervention: Donepezil (cholinesterase inhibitor)
Number of subjects: 1
Study: 10741710

Group type: EXPERIMENTAL
Intervention: GM2-KLH/QS21 vaccine at GM2 doses of 1, 3, 10, 30, or 70 microg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: GM2-KLH/QS21 vaccine at 30 microg dose
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: GM2-KLH/QS21 vaccine (doses of 3-70 microg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Previous vaccine formulation (GM2 and bacille Calmette-Guerin)
Number of subjects: 52
Study: 9007133

Group type: EXPERIMENTAL
Intervention: Paclitaxel 225 mg/m2 via 1-hour infusion and carboplatin (AUC 6.0)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Paclitaxel 135 mg/m2 via 1-hour infusion, cisplatin 60 mg/m2, etoposide 100 mg/m2 (induction chemotherapy) followed by radiation therapy and concurrent chemotherapy
Number of subjects: 100
Study: 1627202

Group type: EXPERIMENTAL
Intervention: Sertaconazole 1% cream, twice a day for 28 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream, twice a day for 28 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study: 6729761

Group type: EXPERIMENTAL
Intervention: Nicergoline 30 mg + placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acebutolol 200 mg + placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acebutolol 400 mg + placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acebutolol 200 mg + nicergoline 15 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nicergoline
Number of subjects: 12
Study: 31656181

Group type: EXPERIMENTAL
Intervention: Maternal depression score and food insecurity
Number of subjects: 3350

Group type: EXPERIMENTAL
Intervention: Family type (nuclear vs. joint)
Number of subjects: 3350

Group type: EXPERIMENTAL
Intervention: Maternal depression score, type of toilet, garbage disposal, household food insecurity, sex
Number of subjects: 3350

Group type: EXPERIMENTAL
Intervention: Maternal depression score, type of toilet, garbage disposal, household food insecurity, sex, perceived overall physical condition of the infant after birth
Number of subjects: 3350
Study: 29924056

Group type: EXPERIMENTAL
Intervention: Cimetropium bromide (5 mg)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 26667245

Group type: EXPERIMENTAL
Intervention: Baseline body fat mass (FM)
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Baseline IGF-1
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Baseline osteocalcin
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Baseline ghrelin
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Baseline leptin
Number of subjects: 633
Study: 25099540

Group type: EXPERIMENTAL
Intervention: HOS + fish oil (FO; 5 g EPA and DHA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HOS + algal oil (AO; 5 g DHA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: high-linoleic acid sunflower oil (HLS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: high-oleic acid sunflower oil (HOS; control)
Number of subjects: 16
Study: 22928960

Group type: EXPERIMENTAL
Intervention: Mentoring intervention (pairing new reviewers with senior reviewers for first three manuscript reviews)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (standard written informational materials)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Mentoring intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 20101008

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate ketogenic diet (LCKD)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Orlistat therapy plus low-fat diet (O + LFD)
Number of subjects: 146
Study: 17405805

Group type: EXPERIMENTAL
Intervention: Ergonomic intervention and informative brochure
Number of subjects: 200

Group type: COMPARATOR
Intervention: Informative brochure only
Number of subjects: 200
Study: 15867009

Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone enanthate (100 mg weekly) plus oral levonorgestrel (31.25 microg daily)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone enanthate (100 mg weekly) plus oral levonorgestrel (62.5 microg daily)
Number of subjects: 41
Study: 12410751

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (2250 mg intramuscular) twice daily for 2 days
Number of subjects: 138

Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg orally) twice daily for 7 days
Number of subjects: 138
Study: 11551252

Group type: EXPERIMENTAL
Intervention: Nasal glucocorticoid beclomethasone (BDP; 400 microg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy control subjects (n=5)
Number of subjects: 16
Study: 9131473

Group type: EXPERIMENTAL
Intervention: Brånemark system (Brå)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IMZ-system
Number of subjects: 60
Study: 7703829

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 10
Study: 2887100

Group type: EXPERIMENTAL
Intervention: Intravenous atenolol
Number of subjects: 16027

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 16027
Study: 30066325

Group type: EXPERIMENTAL
Intervention: Multi-disciplinary intervention group (n = 73)
Number of subjects: 145
Study: 27001985

Group type: EXPERIMENTAL
Intervention: Panobinostat in combination with bortezomib and dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in combination with bortezomib and dexamethasone
Number of subjects: 0
Study: 25897293

Group type: EXPERIMENTAL
Intervention: Intra-operative cell salvage (CS)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (without intra-operative CS)
Number of subjects: 150
Study: 23084272

Group type: EXPERIMENTAL
Intervention: Leaving the PD stent in place for 7 to 10 days (stent group)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Immediate removal of the PD stent after the procedure (stent removed group)
Number of subjects: 151

Group type: COMPARATOR
Intervention: No stent (no stent group)
Number of subjects: 151
Study: 20493653

Group type: EXPERIMENTAL
Intervention: TAXUS Element
Number of subjects: 1262

Group type: COMPARATOR
Intervention: TAXUS Express
Number of subjects: 1262
Study: 18534127

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 13
Study: 16154181

Group type: EXPERIMENTAL
Intervention: Omacor 1 g/day for 3 months (n=37)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Usual care control (n=40)
Number of subjects: 77
Study: 12813118

Group type: EXPERIMENTAL
Intervention: Active AMPT (five 1-g doses administered orally over 28 hours)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (diphenhydramine hydrochloride, five 50-mg doses administered similarly)
Number of subjects: 18
Study: 10872756

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487

Group type: COMPARATOR
Intervention: Lower dose control group
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Higher dose group
Number of subjects: 487
Study: 8686101

Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg
Number of subjects: 60
Study: 1899636

Group type: EXPERIMENTAL
Intervention: Oral streptokinase-streptodornase (SS), dosage: two tablets three times a day for eight days
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 30411802

Group type: EXPERIMENTAL
Intervention: Abnormal cytology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-risk human papillomavirus (HR-HPV) positivity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-testing HR-HPV+ with and without abnormal cytology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPV16+
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPV18+
Number of subjects: 0
Study: 28692476

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass
Number of subjects: 250

Group type: COMPARATOR
Intervention: Laparoscopic gastric banding
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Entire cohort
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 250
Study: 26874901

Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg per day
Number of subjects: 2840

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2840